Evommune EVMN
NYSE EVMN
$6.88 -0.31 (-4.31%)
At close: Oct 2, 2026 · 4:00 PM EDT

Evommune (EVMN) Other Accumulated Expenses (2024 - 2026)

Updated

Evommune's Other Accumulated Expenses was $2.6 million in Q2 2026, up 100.5% from the prior quarter.

Analysis

Evommune (EVMN) Other Accumulated Expenses (2024 - 2026) Analysis & Trends

At the end of FY2025, Other Accumulated Expenses at Evommune came in at $4.93 million, up 35.8% from FY2024.

  • In earlier years, Other Accumulated Expenses was $3.63 million in FY2024.
  • Quarterly Other Accumulated Expenses has moved between $1.3 million (Q1 2026) and $4.93 million (Q4 2025) over five years.
  • Per Business Quant data, EVMN's Other Accumulated Expenses in the three quarters before Q2 2026 was $1.3 million (Q1 2026), $4.93 million (Q4 2025) and $2.85 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Evommune 249.62 Mn -387.90 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.60 Mn
Mar 31, 2026 1.30 Mn
Dec 31, 2025 4.93 Mn
Sep 30, 2025 2.85 Mn
Dec 31, 2024 3.63 Mn
API Access

Evommune Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=EVMN&period=max&api_key=YOUR_API_KEY